Lance Baldo, M.D. is Chief Executive Officer of Beacon Therapeutics, a leading clinical-stage, ocular gene therapy company, founded to save and restore the vision of patients with blinding retinal diseases. Beacon’s lead program, laru-zova, is a late-stage development candidate currently being evaluated in Phase 2/3 trials to treat X-Linked Retinitis Pigmentosa, a severe aggressive inherited retinal disease with no treatment options available. The pipeline also includes two preclinical programs targeting dry age-related macular degeneration (AMD) and an inherited cone-rod dystrophy (CRD). Lance has more than 20 years of leadership experience in biopharmaceuticals including the successful launch of two new indications and a new formulation for Lucentis while at Genentech. Prior to joining Beacon, he served as Chief Medical Officer at Freenome, an early cancer detection company, where he led the design and execution of the Company’s medical strategy to support its pipeline, from clinical trials through registration and commercialization. Lance also served as Chief Medical Officer at Adaptive Biotechnologies, where he helped to lead the transition from a private to publicly traded company as a member of the senior leadership team. He has held numerous roles within the Roche Group and its affiliates, including Senior Vice President and Head of U.S. Medical Affairs of Genentech, Franchise Head for Ophthalmology, and as General Manager for the Roche Pharmaceuticals business in New Zealand. Lance holds an M.D. from the University of Connecticut School of Medicine and a Bachelor of Arts in Biology from Johns Hopkins University.